Table: Taisho Pharmaceutical HD -2018/19 parent results
May 13 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2019 Mar 31, 2018 Mar 31, 2020 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Revenues 15.62 7.24
(+115.7 pct) (+1.5 pct)
Operating 13.68 5.68
(+141.1 pct) (+3.8 pct)
Recurring 13.63 5.61
(+143.0 pct) (+3.7 pct)
Net 30.28 5.53
(+447.2 pct) (-19.3 pct)
EPS 379.01 yen 69.20 yen
EPS Diluted 378.66 yen 69.15 yen
Ann Div 120.00 yen 110.00 yen 110.00 yen
-Q2 Div 50.00 yen 50.00 yen 50.00 yen
-Q4 Div 70.00 yen 60.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10